BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7883799)

  • 1. The D-type cyclins and their role in tumorigenesis.
    Peters G
    J Cell Sci Suppl; 1994; 18():89-96. PubMed ID: 7883799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D-type cyclin-dependent kinase activity in mammalian cells.
    Matsushime H; Quelle DE; Shurtleff SA; Shibuya M; Sherr CJ; Kato JY
    Mol Cell Biol; 1994 Mar; 14(3):2066-76. PubMed ID: 8114738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1.
    Kato JY; Sherr CJ
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11513-7. PubMed ID: 7505440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
    Meyerson M; Harlow E
    Mol Cell Biol; 1994 Mar; 14(3):2077-86. PubMed ID: 8114739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.
    Kato J; Matsushime H; Hiebert SW; Ewen ME; Sherr CJ
    Genes Dev; 1993 Mar; 7(3):331-42. PubMed ID: 8449399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.
    Lukas J; Parry D; Aagaard L; Mann DJ; Bartkova J; Strauss M; Peters G; Bartek J
    Nature; 1995 Jun; 375(6531):503-6. PubMed ID: 7777060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells.
    Sweeney KJ; Sarcevic B; Sutherland RL; Musgrove EA
    Oncogene; 1997 Mar; 14(11):1329-40. PubMed ID: 9178893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin E, a redundant cyclin in breast cancer.
    Gray-Bablin J; Zalvide J; Fox MP; Knickerbocker CJ; DeCaprio JA; Keyomarsi K
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15215-20. PubMed ID: 8986790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes.
    Solvason N; Wu WW; Kabra N; Wu X; Lees E; Howard MC
    J Exp Med; 1996 Aug; 184(2):407-17. PubMed ID: 8760794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential control of cyclins D1 and D3 and the cdk inhibitor p27Kip1 by diverse signalling pathways in Swiss 3T3 cells.
    Mann DJ; Higgins T; Jones NC; Rozengurt E
    Oncogene; 1997 Apr; 14(15):1759-66. PubMed ID: 9150381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins.
    Ewen ME; Sluss HK; Sherr CJ; Matsushime H; Kato J; Livingston DM
    Cell; 1993 May; 73(3):487-97. PubMed ID: 8343202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical interaction of the retinoblastoma protein with human D cyclins.
    Dowdy SF; Hinds PW; Louie K; Reed SI; Arnold A; Weinberg RA
    Cell; 1993 May; 73(3):499-511. PubMed ID: 8490963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation.
    Baker GL; Landis MW; Hinds PW
    Cell Cycle; 2005 Feb; 4(2):330-8. PubMed ID: 15684604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for Cyclin D1 function in G1 progression.
    Tam SW; Theodoras AM; Shay JW; Draetta GF; Pagano M
    Oncogene; 1994 Sep; 9(9):2663-74. PubMed ID: 8058330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-type cyclins.
    Sherr CJ
    Trends Biochem Sci; 1995 May; 20(5):187-90. PubMed ID: 7610482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
    Decker T; Schneller F; Hipp S; Miething C; Jahn T; Duyster J; Peschel C
    Leukemia; 2002 Mar; 16(3):327-34. PubMed ID: 11896535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of G1 progression by D-type cyclins: key event for cell proliferation.
    Kato JY
    Leukemia; 1997 Apr; 11 Suppl 3():347-51. PubMed ID: 9209386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1.
    Lukas J; Müller H; Bartkova J; Spitkovsky D; Kjerulff AA; Jansen-Dürr P; Strauss M; Bartek J
    J Cell Biol; 1994 May; 125(3):625-38. PubMed ID: 8175885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.